Astellas Files For Domestic Approval Of SGLT-2 Inhibitor Ipragliflozin
This article was originally published in PharmAsia News
Executive Summary
Astellas has filed for the approval of their newly development SGLT-2 inhibitor ipragliflozin, development code ASP1941, for the treatment of type 2 diabetes, the company announced on March 13.